254 related articles for article (PubMed ID: 30251131)
1. Risk of secondary primary malignancies in multiple myeloma patients with or without autologous stem cell transplantation.
Yamasaki S; Yoshimoto G; Kohno K; Henzan H; Aoki T; Tanimoto K; Sugio Y; Muta T; Kamimura T; Ohno Y; Ogawa R; Eto T; Nagafuji K; Miyamoto T; Akashi K; Iwasaki H;
Int J Hematol; 2019 Jan; 109(1):98-106. PubMed ID: 30251131
[TBL] [Abstract][Full Text] [Related]
2. Second primary malignancies in multiple myeloma: an overview and IMWG consensus.
Musto P; Anderson KC; Attal M; Richardson PG; Badros A; Hou J; Comenzo R; Du J; Durie BGM; San Miguel J; Einsele H; Chen WM; Garderet L; Pietrantuono G; Hillengass J; Kyle RA; Moreau P; Lahuerta JJ; Landgren O; Ludwig H; Larocca A; Mahindra A; Cavo M; Mazumder A; McCarthy PL; Nouel A; Rajkumar SV; Reiman A; Riva E; Sezer O; Terpos E; Turesson I; Usmani S; Weiss BM; Palumbo A;
Ann Oncol; 2017 Feb; 28(2):228-245. PubMed ID: 27864218
[TBL] [Abstract][Full Text] [Related]
3. Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma.
Mian I; Milton DR; Shah N; Nieto Y; Popat UR; Kebriaei P; Parmar S; Oran B; Shah JJ; Manasanch EE; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH; Bashir Q
Cancer; 2016 Dec; 122(24):3831-3837. PubMed ID: 27680710
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
5. Lenalidomide vs bortezomib maintenance choice post-autologous hematopoietic cell transplantation for multiple myeloma.
Huang J; Phillips S; Byrne M; Chinratanalab W; Engelhardt BG; Goodman SA; Harrell SL; Jagasia M; Kassim A; Rawling KT; Savani BN; Sengsayadeth S; Cornell RF
Bone Marrow Transplant; 2018 Jun; 53(6):701-707. PubMed ID: 29703965
[TBL] [Abstract][Full Text] [Related]
6. Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial.
Jones JR; Cairns DA; Menzies T; Pawlyn C; Davies FE; Sigsworth R; Brioli A; Jenner MW; Kaiser MF; Olivier C; Reed M; Drayson MT; Owen RG; Boyd KD; Cook G; Morgan GJ; Jackson GH;
EClinicalMedicine; 2023 Aug; 62():102099. PubMed ID: 37554123
[TBL] [Abstract][Full Text] [Related]
7. Second primary malignancies after autologous hematopoietic cell transplantation for multiple myeloma.
Krishnan AY; Mei M; Sun CL; Thomas SH; Teh JB; Kang T; Htut M; Somlo G; Sahebi F; Forman SJ; Bhatia S
Biol Blood Marrow Transplant; 2013 Feb; 19(2):260-5. PubMed ID: 23073267
[TBL] [Abstract][Full Text] [Related]
8. Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents.
Sahebi F; Iacobelli S; Sbianchi G; Koster L; Blaise D; Reményi P; Russell NH; Ljungman P; Kobbe G; Apperley J; Trneny M; Krejci M; Wiktor-Jedrzejczak W; Sanchez JF; Schaap N; Isaksson C; Lenhoff S; Browne P; Scheid C; Wilson KMO; Yakoub-Agha I; Muñiz SG; Schönland S; Morris C; Garderet L; Kröger N
Biol Blood Marrow Transplant; 2018 May; 24(5):930-936. PubMed ID: 29339268
[TBL] [Abstract][Full Text] [Related]
9. FDA Approval Summary: Lenalidomide as Maintenance Therapy After Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma.
Pulte ED; Dmytrijuk A; Nie L; Goldberg KB; McKee AE; Farrell AT; Pazdur R
Oncologist; 2018 Jun; 23(6):734-739. PubMed ID: 29438096
[TBL] [Abstract][Full Text] [Related]
10. Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial.
van de Donk NW; van der Holt B; Minnema MC; Vellenga E; Croockewit S; Kersten MJ; von dem Borne PA; Ypma P; Schaafsma R; de Weerdt O; Klein SK; Delforge M; Levin MD; Bos GM; Jie KG; Sinnige H; Coenen JL; de Waal EG; Zweegman S; Sonneveld P; Lokhorst HM
Lancet Haematol; 2018 Oct; 5(10):e479-e492. PubMed ID: 30290905
[TBL] [Abstract][Full Text] [Related]
11. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.
Attal M; Lauwers-Cances V; Marit G; Caillot D; Moreau P; Facon T; Stoppa AM; Hulin C; Benboubker L; Garderet L; Decaux O; Leyvraz S; Vekemans MC; Voillat L; Michallet M; Pegourie B; Dumontet C; Roussel M; Leleu X; Mathiot C; Payen C; Avet-Loiseau H; Harousseau JL;
N Engl J Med; 2012 May; 366(19):1782-91. PubMed ID: 22571202
[TBL] [Abstract][Full Text] [Related]
12. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data.
Palumbo A; Bringhen S; Kumar SK; Lupparelli G; Usmani S; Waage A; Larocca A; van der Holt B; Musto P; Offidani M; Petrucci MT; Evangelista A; Zweegman S; Nooka AK; Spencer A; Dimopoulos MA; Hajek R; Cavo M; Richardson P; Lonial S; Ciccone G; Boccadoro M; Anderson K; Barlogie B; Sonneveld P; McCarthy PL
Lancet Oncol; 2014 Mar; 15(3):333-42. PubMed ID: 24525202
[TBL] [Abstract][Full Text] [Related]
13. Safety of live-attenuated measles-mumps-rubella and herpes zoster vaccination in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantation.
Pandit A; Leblebjian H; Hammond SP; Laubach JP; Richardson PG; Baden LR; Marty FM; Issa NC
Bone Marrow Transplant; 2018 Jul; 53(7):942-945. PubMed ID: 29426830
[TBL] [Abstract][Full Text] [Related]
14. Prolonged survival with increasing duration of lenalidomide maintenance after autologous transplant for multiple myeloma.
Amsler IG; Jeker B; Mansouri Taleghani B; Bacher U; Betticher D; Egger T; Zander T; Luethi JM; Novak U; Pabst T
Leuk Lymphoma; 2019 Feb; 60(2):511-514. PubMed ID: 30616438
[No Abstract] [Full Text] [Related]
15. Lenalidomide: A Review in Newly Diagnosed Multiple Myeloma as Maintenance Therapy After ASCT.
Syed YY
Drugs; 2017 Sep; 77(13):1473-1480. PubMed ID: 28791622
[TBL] [Abstract][Full Text] [Related]
16. Second primary malignancies in patients with haematological cancers treated with lenalidomide: a systematic review and meta-analysis.
Saleem K; Franz J; Klem ML; Yabes JG; Boyiadzis M; Jones JR; Shaikh N; Lontos K
Lancet Haematol; 2022 Dec; 9(12):e906-e918. PubMed ID: 36354020
[TBL] [Abstract][Full Text] [Related]
17. Post-transplant consolidation plus lenalidomide maintenance vs lenalidomide maintenance alone in multiple myeloma: A systematic review.
Al-Ani F; Louzada M
Eur J Haematol; 2017 Dec; 99(6):479-488. PubMed ID: 28885719
[TBL] [Abstract][Full Text] [Related]
18. Results from Two Consecutive Studies of Consolidation Therapy after Autologous Transplant for Multiple Myeloma: Thalidomide, Dexamethasone, and Clarithromycin or Lenalidomide, Dexamethasone, and Clarithromycin.
Holmberg LA; Becker PS; Bensinger W
Acta Haematol; 2017; 137(3):123-131. PubMed ID: 28355602
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.
Manasanch EE; Shah JJ; Lee HC; Weber DM; Thomas SK; Amini B; Feng L; Berkova Z; Hildebrandt M; Orlowski RZ
Lancet Haematol; 2018 Dec; 5(12):e628-e640. PubMed ID: 30501870
[TBL] [Abstract][Full Text] [Related]
20. A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma.
Mark TM; Guarneri D; Forsberg P; Rossi A; Pearse R; Perry A; Pekle K; Tegnestam L; Greenberg J; Shore T; Gergis U; Mayer S; Van Besien K; Ely S; Jayabalan D; Sherbenou D; Coleman M; Niesvizky R
Biol Blood Marrow Transplant; 2017 Jun; 23(6):930-937. PubMed ID: 28285081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
